Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients

The Pharmacogenomics Journal volume 8, pages 139–146 (2008)Cite this article

Abstract

Previously studied candidate genes have failed to account for inter-individual variability of docetaxel and doxorubicin disposition and effects. We genotyped the transcriptional regulators of CYP3A and ABCB1 in 101 breast cancer patients from 3 Asian ethnic groups, that is, Chinese, Malays and Indians, in correlation with the pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin. While there was no ethnic difference in docetaxel and doxorubicin pharmacokinetics, ethnic difference in docetaxel- (ANOVA, P=0.001) and doxorubicin-induced (ANOVA, P=0.003) leukocyte suppression was observed, with Chinese and Indians experiencing greater degree of docetaxel-induced myelosuppression than Malays (Bonferroni, P=0.002, P=0.042), and Chinese experiencing greater degree of doxorubicin-induced myelosuppression than Malays and Indians (post hoc Bonferroni, P=0.024 and 0.025). Genotyping revealed both PXR and CAR to be well conserved; only a PXR 5′-untranslated region polymorphism (−24381A>C) and a silent CAR variant (Pro180Pro) were found at allele frequencies of 26 and 53%, respectively. Two non-synonymous variants were identified in HNF4α (Met49Val and Thr130Ile) at allele frequencies of 55 and 1%, respectively, with the Met49Val variant associated with slower neutrophil recovery in docetaxel-treated patients (ANOVA, P=0.046). Interactions were observed between HNF4α Met49Val and CAR Pro180Pro, with patients who were wild type for both variants experiencing least docetaxel-induced neutropenia (ANOVA, P=0.030). No other significant genotypic associations with pharmacokinetics or pharmacodynamics of either drug were found. The PXR-24381A>C variants were significantly more common in Indians compared to Chinese or Malays (32/18/21%, P=0.035) Inter-individual and inter-ethnic variations of docetaxel and doxorubicin pharmacokinetics or pharmacodynamics exist, but genotypic variability of the transcriptional regulators PAR, CAR and HNF4α cannot account for this variability.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–254.

    Article  CAS  PubMed  Google Scholar 

  2. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272.

    Article  CAS  PubMed  Google Scholar 

  3. Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ . CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. Am J Cardiol 2004; 93: 104–107.

    Article  CAS  PubMed  Google Scholar 

  4. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373–388.

    Article  CAS  PubMed  Google Scholar 

  5. Sakaeda T, Nakamura T, Okumura K . Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 2003; 4: 397–410.

    Article  CAS  PubMed  Google Scholar 

  6. Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR et al. A variant 2677A allele of the MDR1 gene affects fexofenadine disposition. Clin Pharmacol Ther 2004; 76: 418–427.

    Article  CAS  PubMed  Google Scholar 

  7. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al. Identification of functionally variant mdr1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70: 189–199.

    Article  CAS  PubMed  Google Scholar 

  8. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683–3690.

    Article  CAS  PubMed  Google Scholar 

  9. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 1998; 92: 73–82.

    Article  CAS  PubMed  Google Scholar 

  10. Goodwin B, Redinbo MR, Kliewer SA . Regulation of cyp3a gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1–23.

    Article  CAS  PubMed  Google Scholar 

  11. Kliewer SA, Goodwin B, Willson TM . The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687–702.

    Article  CAS  PubMed  Google Scholar 

  12. Willson TM, Kliewer SA . PXR, CAR and drug metabolism. Nat Rev Drug Discov 2002; 1: 259–266.

    Article  CAS  PubMed  Google Scholar 

  13. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V et al. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9: 220–224.

    Article  CAS  PubMed  Google Scholar 

  14. Wang H, LeCluyse EL . Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003; 42: 1331–1357.

    Article  CAS  PubMed  Google Scholar 

  15. Jiang G, Sladek FM . The DNA binding domain of hepatocyte nuclear factor 4 mediates cooperative, specific binding to DNA and heterodimerization with the retinoid X receptor alpha. J Biol Chem 1997; 272: 1218–1225.

    Article  CAS  PubMed  Google Scholar 

  16. Jover R, Bort R, Gomez-Lechon MJ, Castell JV . Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001; 33: 668–675.

    Article  CAS  PubMed  Google Scholar 

  17. Lausen J, Thomas H, Lemm I, Bulman M, Borgschulze M, Lingott A et al. Naturally occurring mutations in the human HNF4alpha gene impair the function of the transcription factor to a varying degree. Nucleic Acids Res 2000; 28: 430–437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lamba J, Lamba V, Schuetz E . Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 2005; 6: 369–383.

    Article  CAS  PubMed  Google Scholar 

  19. Andersen A, Holte H, Slordal L . Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol 1999; 44: 422–426.

    Article  CAS  PubMed  Google Scholar 

  20. Clarke SJ, Rivory LP . Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999; 36: 99–114.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555–572.

    Article  CAS  PubMed  Google Scholar 

  22. Bosch TM, Deenen M, Pruntel R, Smits PH, Schellens JH, Beijnen JH et al. Screening for polymorphisms in the PXR gene in a Dutch population. Eur J Clin Pharmacol 2006; 62: 395–399.

    Article  CAS  PubMed  Google Scholar 

  23. Koyano S, Kurose K, Ozawa S, Saeki M, Nakajima Y, Hasegawa R et al. Eleven novel single nucleotide polymorphisms in the NR1I2 (PXR) gene, four of which induce non-synonymous amino acid alterations. Drug Metab Pharmacokinet 2002; 17: 561–565.

    Article  PubMed  Google Scholar 

  24. Lee SC, Ng SS, Oldenburg J, Chong PY, Rost S, Guo JY et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006; 79: 197–205.

    Article  CAS  PubMed  Google Scholar 

  25. Ek J, Rose CS, Jensen DP, Glumer C, Borch-Johnsen K, Jorgensen T et al. The functional Thr130Ile and Val255Met polymorphisms of the hepatocyte nuclear factor-4alpha (HNF4A): gene associations with type 2 diabetes or altered beta-cell function among danes. J Clin Endocrinol Metab 2005; 90: 3054–3059.

    Article  CAS  PubMed  Google Scholar 

  26. Pruhova S, Ek J, Lebl J, Sumnik Z, Saudek F, Andel M et al. Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia 2003; 46: 291–295.

    Article  CAS  PubMed  Google Scholar 

  27. Green VJ, Kokkotou E, Ladias JA . Critical structural elements and multitarget protein interactions of the transcriptional activator AF-1 of hepatocyte nuclear factor 4. J Biol Chem 1998; 273: 29950–29957.

    Article  CAS  PubMed  Google Scholar 

  28. Eeckhoute J, Formstecher P, Laine B . Maturity-onset diabetes of the young Type 1 (MODY1)-associated mutations R154X and E276Q in hepatocyte nuclear factor 4alpha (HNF4alpha) gene impair recruitment of p300, a key transcriptional co-activator. Mol Endocrinol 2001; 15: 1200–1210.

    CAS  PubMed  Google Scholar 

  29. Eeckhoute J, Moerman E, Bouckenooghe T, Lukoviak B, Pattou F, Formstecher P et al. Hepatocyte nuclear factor 4 alpha isoforms originated from the P1 promoter are expressed in human pancreatic beta-cells and exhibit stronger transcriptional potentials than P2 promoter-driven isoforms. Endocrinology 2003; 144: 1686–1694.

    Article  CAS  PubMed  Google Scholar 

  30. Kistanova E, Dell H, Tsantili P, Falvey E, Cladaras C, Hadzopoulou-Cladaras M . The activation function-1 of hepatocyte nuclear factor-4 is an acidic activator that mediates interactions through bulky hydrophobic residues. Biochem J 2001; 356: 635–642.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhu Q, Yamagata K, Miura A, Shihara N, Horikawa Y, Takeda J et al. T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003; 46: 567–573.

    Article  CAS  PubMed  Google Scholar 

  32. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 2006; 12: 5786–5793.

    Article  CAS  PubMed  Google Scholar 

  33. Guitton J, Cohen S, Tranchand B, Vignal B, Droz JP, Guillaumont M et al. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005; 19: 2419–2426.

    Article  CAS  PubMed  Google Scholar 

  34. Andersen A, Warren DJ, Slordal L . A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 1993; 15: 455–461.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Biomedical Research Council of Singapore (BMRC 01/1/26/18/060) and Singapore Cancer Syndicate (SCS-PN0022).

Author information

Authors and Affiliations

  1. Department of Biochemistry, National University of Singapore, Singapore

    S Y Hor & T Tan

  2. Department of Haematology-Oncology, National University Hospital, Singapore

    S C Lee, C I Wong, Y W Lim, R C Lim, L Z Wang, J Y Guo & B C Goh

  3. Department of Pharmacology, National University of Singapore, Singapore

    L Fan & H S Lee

Authors
  1. S Y Hor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S C Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C I Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y W Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R C Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Z Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Y Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. H S Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B C Goh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B C Goh.

Additional information

Duality of Interest

All authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hor, S., Lee, S., Wong, C. et al. PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 8, 139–146 (2008). https://doi.org/10.1038/sj.tpj.6500478

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500478

Keywords

This article is cited by

Search

Advanced search

Quick links